Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Accumulated Expenses (2021 - 2025)

Biofrontera has reported Accumulated Expenses over the past 5 years, most recently at $2.8 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 15.53% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, up 15.53%, while the annual FY2025 figure was $2.8 million, 15.53% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $2.8 million at Biofrontera, down from $3.0 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $5.6 million in Q4 2021 and troughed at $2.4 million in Q2 2025.
  • A 5-year average of $3.7 million and a median of $2.8 million in 2025 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: crashed 55.36% in 2022 and later increased 15.53% in 2025.
  • Year by year, Accumulated Expenses stood at $5.6 million in 2021, then crashed by 55.36% to $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then decreased by 2.88% to $2.4 million in 2024, then rose by 15.53% to $2.8 million in 2025.
  • Business Quant data shows Accumulated Expenses for BFRI at $2.8 million in Q4 2025, $3.0 million in Q3 2025, and $2.4 million in Q2 2025.